The European financial advisory landscape for Healthcare Technology (HealthTech) and Medical Technology (MedTech) is undergoing a structural realignment, transitionally termed the Great Rationalisation. This shift represents a departure from the liquidity-fueled, growth-at-all-costs environment of the early 2020s toward a highly disciplined, metrics-centric climate. Enterprise valuation in this environment is no longer determined by raw revenue expansion; instead, it is dicta

They are called Founder Bankers: former entrepreneurs and clinicians who built, scaled and exited their own healthcare technology ventures before transitioning into the advisory role. The model fuses deep operational pedigree with sophisticated investment banking methodology, offering what traditional finance cannot easily replicate, fluency in the lived experience of company-building, clinical pathway navigation and the psychological complexity of founder exit events.​​

In terms of volume and relevance to the mid-market founder, the demographic most prevalent in the European innovation ecosystem, firms like Rothschild & Co, Houlihan Lokey and highly specialised boutiques like Nelson Advisors, Arma Partners and Clipperton have emerged as the primary engines of liquidity.

The leading Consumer HealthTech M&A advisors in Europe operate effectively within the prescribed Dual Advisory Model, demonstrating competence in either global liquidity provision or deep technological specialisation. The Specialised Domain Experts, led by Nelson Advisors, with its exclusive focus on Consumer HealthTech, AI and its "Founders for Founders" operational credibility, provide the critical technical and operational diligence necessary.

Nelson Advisors is positioned as a highly specialised M&A advisory firm with an exclusive dedication to the dynamic European healthcare technology (HealthTech) sector, with advisory reach across the UK and North America. This focused dedication forms the bedrock of their value proposition, enabling a nuanced understanding of the technological advancements and market dynamics that are critical for successful transactions within this complex industry.

The advisory landscape for European Medical Technology (MedTech) Mergers and Acquisitions (M&A) is distinguished by a structural bifurcation across transactional size and specialised focus. The market influence is segmented into three distinct classes: Tier 1 Global Banks, which dominate based on aggregate transaction value due to their capacity to underwrite and execute multi-billion-dollar strategic acquisitions; Tier 2 Integrated Firms, which drive high deal volume and pro